39th week of 2011 patent applcation highlights part 45 |
Patent application number | Title | Published |
20110236377 | Hepatocyte Growth Factor (HGF) Binding Proteins - The present invention provides a family of binding proteins that bind and neutralize the activity of hepatocyte growth factor (HGF), in particular human HGF. The binding proteins can be used as diagnostic and/or therapeutic agents. With regard to their therapeutic activity, the binding proteins can be used to treat certain HGF responsive disorders, for example, certain HGF responsive tumors. | 2011-09-29 |
20110236378 | NON-HUMAN MAMMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES - The invention provides knock-in non-human cells and mammals having a genome encoding chimeric antibodies and methods of producing knock-in cells and mammals. Certain aspects of the invention include chimeric antibodies, humanized antibodies, pharmaceutical compositions and kits. Certain aspects of the invention also relate to diagnostic and treatment methods using the antibodies of the invention. | 2011-09-29 |
20110236379 | PHARMACEUTICAL COMBINATIONS COMPRISING A PYRIDO [4,3-D] PYRIMIDINE DERIVED HSP90-INHIBITOR AND A HER2 INHIBITOR - A pharmaceutical combination comprising an Hsp90 inhibitor and an HER2 inhibitor, and methods of using the combination to treat proliferative disorders. | 2011-09-29 |
20110236380 | LIGANDS THAT BIND IL-13 - Disclosed are ligands that have binding specificity for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating IL-13-mediated conditions, such as lung conditions, eg allergic asthma, is described. The ligands have potent IL-13 binding kinetics. Ligands are described that are cross-reactive between human IL-13 and one or more primate IL-13. Ligands are well expressed in prokaryotic cells. | 2011-09-29 |
20110236381 | INHIBITION OF INTER-ALPHA TRYPSIN INHIBITOR FOR THE TREATMENT OF AIRWAY DISEASE - It is disclosed herein that blockade of inter-alpha-trypsin inhibitor (IaI) prevents the development of airway hyperresponsiveness in animal models of asthma and chronic obstructive pulmonary disease. Provided herein are methods of treating an airway disease or disorder in a subject by administering to the subject a therapeutically effective amount of an inhibitor of IaI. Also provided is a method of preventing or reducing airway hyperresponsiveness in a subject by administering to the subject a therapeutically effective amount of an inhibitor of IaI. The IaI inhibitor can be any compound that inhibits the expression or activity of IaI or a gene encoding an IaI polypeptide. In some embodiments, the IaI inhibitor is administered locally to the airway of the subject in need of treatment. For example, the inhibitor can be administered by aerosol delivery, such as by using an inhaler or nebulizer. | 2011-09-29 |
20110236382 | IMMUNOSUPPRESSIVE COMBINATION AND ITS USE IN THE TREATMENT OR PROPHYLAXIS OF INSULIN-PRODUCING CELL GRAFT REJECTION - A pharmaceutical combination comprising an accelerated lymphocyte homing agent in free form or in pharmaceutically acceptable salt form, and one or more compounds selected from the group consisting of an antibody to the IL-2 receptor, an immunosuppressive macrocyclic lactone and a soluble human complement inhibitor is used to treat or prevent insulin-producing cell graft rejection. | 2011-09-29 |
20110236383 | Protein Formulation - A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein. | 2011-09-29 |
20110236384 | DIRECT DRUG DELIVERY SYSTEM BASED ON THERMALLY RESPONSIVE BIOPOLYMERS - A method for delivering a drug depot of a compound of interest to a selected region in a subject. The method comprises administering a composition directly to said region of interest, the composition comprising the compound of interest to be delivered (such as an antiinflammatory agent or a chemotherapeutic agent) and a polymer (such as an elastin-like peptide or ELP) that undergoes an inverse temperature phase transition, so that a sustained release of the compound of interest at the selected region is provided. Compositions useful for carrying out the invention are also described. | 2011-09-29 |
20110236385 | BLOCKING MESOTHELIN PEPTIDE FRAGMENTS - The present invention provides mesothelin peptide fragments corresponding to the CA125 binding site of mesothelin. The peptide fragments find use in disrupting the binding interaction between mesothelin and CA 125, for example, in the treatment and prevention of cancers that require the interaction of mesothelin and CA125 for growth, progression and/or metastasis. | 2011-09-29 |
20110236386 | NOVEL METHOD FOR PREDICTION OF CARDIOVASCULAR DISEASE RISK IN TYPE 2 DIABETES - The invention provides a method for diagnosing an increased risk of cardiovascular disease (CVD, including coronary heart disease (CHD)) in patients with type 2 diabetes comprising detecting basic fibroblast growth factor (bFGF) in a sample from the patient, an increased level of bFGF being indicative of increased risk of CHD, thereby diagnosing an increased risk of CHD in diabetic patients. | 2011-09-29 |
20110236387 | POLYPEPTIDES AND ANTIBODIES DERIVED FROM CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND USES THEREOF - Small animal models for assessing immunomodulatory effects of compounds are provided. | 2011-09-29 |
20110236388 | BISPECIFIC, BIVALENT ANTI-VEGF/ANTI-ANG-2 ANTIBODIES - The present invention relates to bispecific, bivalent antibodies against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2011-09-29 |
20110236389 | Human Angiostatin Interacting and Tumor Metastasis Involving Protein Variants and Uses Thereof - The invention provides human angiostatin interacting and tumor metastasis involving protein (HAI-TMIP) isoforms, namely HAI-TMIP variants 1 to 7, and human protein complexes comprising HAI-TMIP variant 1, 2, 3, 4, 5, 6 or 7. The invention also provides antibodies that immunospecifically bind to HAI-TMIP variant 1, 2, 3, 4, 5, 6 or 7 or a complex comprising such a variant, and uses of such antibodies. The present invention provides peptides which may be used as immunogens to distinguish between the HAI-TMIP variants. The invention further provides compounds that modulate the expression and/or activity of HAI-TMIP variant 1, 2, 3, 4, 5, 6 or 7, or a complex comprising such a variant, and uses of such compounds in the prevention, treatment and/or management of various disorders, in particular, cancer. | 2011-09-29 |
20110236390 | IL-17A Antagonists - Interleukin-17A (IL-17A) antibody antagonists, polynucleotides encoding IL-17A antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed. | 2011-09-29 |
20110236391 | METHOD FOR OBTAINING AN EXCIPIENT-FREE ANTIBODY SOLUTION - The present invention relates to a method of ultra- and dialfiltrating an antibody solution containing at least one solute in addition to the antibody, which comprises diafiltrating the antibody solution with a solvent and bringing said mixture into contact with a semi-permeable membrane so as to allow the at least one solute present in the antibody solution and having a molecular weight lower than the molecular weight cut-off of the membrane to pass through the membrane, whilst retaining the antibody so that a modified antibody solution is obtained that only contains the antibody and the solvent. | 2011-09-29 |
20110236392 | COMPOSITION AND METHOD FOR TREATMENT OF PRETERM LABOR - The invention provides a method for treating or preventing preterm labor in pregnant female subjects. The method comprises the step of administering a therapeutically effective amount of a Toll-like Receptor 9 antagonist sufficient to prevent the activation of Toll-like Receptor 9 by fetal DNA. The invention further provides compositions comprising a Toll-like Receptor 9 antagonist for use in the methods of the invention. Said compositions and methods enhance gestation and therefore improve neonatal morbidity and mortality. | 2011-09-29 |
20110236393 | MONOCLONAL ANTIBODY PRODUCTION IN B CELLS AND USES THEROF - The presently disclosed subject matter provides methods of inhibiting a host innate response to activator-mediated proliferative signals in a primary B cell. In some embodiments a method is provided for immortalized primary B cells. In some embodiments a method is provided for increasing efficiency of EBV transformation of primary B cells. In some embodiments a method is provided for increasing proliferation of primary B cells in culture. In some embodiments a method is provided for producing a monoclonal antibody. In some embodiments a method is provided for identifying a novel broadly neutralizing antibody having a desired antigen specificity. Also provided are antibodies produced according the methods of the presently disclosed subject matter. | 2011-09-29 |
20110236394 | METHODS FOR THE REGULATION OF THE PROSTAGLANDIN F SYNTHASE (PGFS) ACTIVITY OF AKR1B1 AND USES THEREOF - AKR1B1 (EC 1.1.1.21) is an aldose reductase that has mainly been associated with the polyol pathway, and more recently with lipid deperoxidation. We have discovered that the primary activity of this enzyme is rather a PGFS activity, catalyzing the transformation of PGH | 2011-09-29 |
20110236395 | TREATMENT OF FIBROTIC EYE DISORDERS USING AN MMP2 INHIBITOR - Inhibitors of matrix metalloproteinase 2 are used to treat or prevent a fibrotic disorder of the posterior capsule of the eye, for example posterior capsule opacification (PCO), or of a tissue or structure of the eye other than the lens or capsular bag. | 2011-09-29 |
20110236396 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING A COLORECTAL ADENOCARCINOMA - The present invention relates to in vitro methods and compositions for diagnosing and/or treating a colorectal adenocarcinoma associated with a chromosomal aberration on chromosome 20q and/or the predisposition for developing such an adenocarcinoma by determining the expression levels of a set of particular marker genes, wherein an elevated expression level of the marker genes in a test sample as compared to a control level is indicative of a colorectal adenocarcinoma. | 2011-09-29 |
20110236397 | LIMITED PROTEOLYSIS OF CD2AP AND PROGRESSION OF RENAL DISEASE - Compositions which specifically block cathepsin L function in podocytes, compositions which protect cytoskeletal adaptor protein (CD2AP) for degradation, compositions which modulate expression or function of cytoskeletal adaptor protein (CD2AP), protect against renal diseases or disorders. Methods of treatment in vivo involve use of one or more compositions. | 2011-09-29 |
20110236398 | Antibody Formulation - The present invention relates to novel pharmaceutical formulations, in particular novel pharmaceutical formulations in which the active ingredient comprises human antibodies to human interleukin 1 beta (IL-1β), in particular ACZ885 antibody, pharmaceutical formulations which are stable and aggregate-free upon storage and delivery. | 2011-09-29 |
20110236399 | COMPOSITIONS AND METHODS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTION - This invention is directed to compositions and methods for treating (e.g., prophylactically and/or therapeutically) infection in a preterm infant. In particular, the invention provides anti-lipoteichoic acid (LTA) antibody compositions and methods of administering the same to a preterm infant (e.g., a low birth weight preterm infant (e.g., a very low birth weight preterm infant)) under conditions to establish anti-LTA antibody serum concentrations effective to kill and/or prevent growth of bacteria (e.g., Staphylococci). Compositions and methods of the invention find use in, among other things, clinical (e.g. therapeutic and preventative medicine) and research applications. | 2011-09-29 |
20110236400 | TETRAHYDROPYRANOCHROMENE GAMMA SECRETASE INHIBITORS - Disclosed are novel gamma secretase inhibitors of the formula. Also disclosed are methods of inhibiting gamma-secretase, methods of treating neurodegenerative diseases, and methods of treating Alzheimer's Disease. Also disclosed are processes for preparing alkenes in one reaction step using a mixture of an aldehyde (or ketone) and an alkyl substituted with two electron withdrawing groups, and reacting the mixture with: (a) a sulfonyl halide (e.g., a sulfonyl chloride) and a basic tertiary amine, or, (b) a sulfonyl anhydride and a basic amine, or (c) an aryl-C(O)-halide and a basic tertiary amine, or (d) an aryl-C(O)—O—C(O)-aryl and a basic tertiary amine, or (e) an heteroaryl-C(O)-halide and a basic tertiary amine, or (f) a heteroaryl-C(O)—O—C(O)-heteroaryl and a basic tertiary amine. | 2011-09-29 |
20110236401 | COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY - The invention derives from the identification of HVEM as the native ligand for BTLA. The invention provides compositions and methods for modulating BTLA-HVEM interactions and BTLA and HVEM activity, which are useful for modulating immune responses. Agonists and antagonists of the BTLA-HVEM interaction are provided, and methods of treating a variety of conditions through the modulation of immune responses are provided. | 2011-09-29 |
20110236402 | ENHANCEMENT OF LIGHT ACTIVATED THERAPY BY IMMUNE AUGMENTATION USING ANTI-CTLA-4 ANTIBODY - The efficacy of light activated therapy treatment is enhanced by stimulating the immune system of the patient substantially above a normal level. Abnormal tissue that is destroyed by the light activated therapy releases factors that stimulate the immune system, leading to systemic reductions in abnormal tissue (i.e., reduction beyond the region treated using light). By further stimulating the immune system using an anti-CTLA-4 antibody, the systemic destruction of abnormal tissue is enhanced. | 2011-09-29 |
20110236403 | TARGETING PAX2 FOR THE INDUCTION OF DEFB1-MEDIATED TUMOR IMMUNITY AND CANCER THERAPY - Provided is a method of treating cancer in a subject by inhibiting expression of PAX2. An example of a cancer treated by the present method is prostate cancer. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. | 2011-09-29 |
20110236404 | Methods for Protein Expression in Mammalian Cells in Serum-Free Medium - Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transfection under serum-free conditions. In preferred embodiments, the cells of use are SpESF or SpESF-X cells. | 2011-09-29 |
20110236405 | COAGULATION FACTOR MODULATION FOR CONTROLLING TRANSPLANT ORGAN SIZE - A method of modulating transplant organ size in a subject in need thereof is disclosed. The method comprising: (a) administering to the subject an agent capable of modulating an activity or expression of a coagulation factor or an effector thereof; and (b) transplanting the organ into the subject; thereby modulating the transplant organ size in the subject. | 2011-09-29 |
20110236406 | IMMUNOGENIC COMPOSITIONS COMPRISING HMGB1 POLYPEPTIDES - The present invention relates to novel immunogenic compositions (e.g., vaccines), the production of such immunogenic compositions and methods of using such compositions. More specifically, this invention provides unique immunogenic molecules comprising an HMGB1 polypeptide (e.g., an HMGB1 B-box polypeptide) and an antigen. Even more specifically, this invention provides novel fusion proteins comprising an isolated HMGB1 polypeptide and an antigen such that administration of these fusion proteins provides the two signals required for native T-cell activation. | 2011-09-29 |
20110236407 | VACCINE FOR RUNTING-STUNTING SYNDROME - The present invention includes polypeptides, polynucleotides, antibodies, and vaccines associated with Runting Stunting Syndrome (RSS) in poultry. The present invention also includes diagnostic methods based on such polypeptides, polynucleotides, and antibodies and methods of protecting poultry, including chickens, against RSS by the administration of such polypeptides, polynucleotides, antibodies, and vaccines. | 2011-09-29 |
20110236408 | RESPIRATORY SYNCTIAL VIRUS (RSV) SEQUENCES FOR PROTEIN EXPRESSION AND VACCINES - The invention provides RSV fusion (F) protein ectodomain polypeptide sequences and nucleotide sequences encoding them, as well as cells containing the invention's polypeptide and nucleotide sequences. The invention further provides VLPs that contain the invention's polypeptides, and methods for using the VLPs for protein expression and vaccine formulation. Also provided are methods for distinguishing between subjects immunized with the invention's compositions and subjects infected with RSV. | 2011-09-29 |
20110236409 | OVERLAPPING PEPTIDES FROM VARIABLE ANTIGENS, T CELL POPULATIONS AND USES THEREOF - The present invention relates to set overlapping immunogenic peptides of a variable antigen, and uses thereof, in particular for diagnostic and therapeutic purposes. The present invention relates also to a sub-population of CD8 T cells associated with the non-progressive status in HIV-infected subjects. | 2011-09-29 |
20110236410 | KLEBSIELLA ANTIGENS - The present invention relates to isolated nucleic acid molecules which encode an antigen, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a | 2011-09-29 |
20110236411 | MHC Multimers in Tuberculosis Diagnostics, Vaccine and Therapeutics - The present invention relates to MHC-peptide complexes and uses thereof in the diagnosis of, treatment of or vaccination against a disease in an individual. More specifically the invention discloses MHC complexes comprising | 2011-09-29 |
20110236412 | Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine - A method for preserving a polypeptide comprises (i) providing an aqueous solution of one or more sugars, a polyethyleneimine and said polypeptide wherein the concentration of polyethyleneimine is 25 μM or less based on the number-average molar mass (Mn) of the polyethyleneimine and the sugar concentration or, if more than one sugar is present, total sugar concentration is greater than 0.1 M; and (ii) drying the solution to form an amorphous solid matrix comprising said polypeptide. | 2011-09-29 |
20110236413 | METHODS AND COMPOSITIONS TO REDUCE FAT GAIN, PROMOTE WEIGHT LOSS IN ANIMALS - The present disclosure relates to compositions and related methods to reduce body weight, body fat, waist and hip size, plasma total cholesterol, LDL, triglycerides, blood glucose, leptin and C-reactive protein levels and increase in HDL and serotonin levels in an mammal. The LeptiCore® formulation disclosed, at both the low and high dosages, is helpful in the management of fat gain and its related complications. The higher dosage resulted in significantly greater reductions in body weight and triglyceride, blood glucose, and C-reactive protein levels, as well as increased serotonin levels. | 2011-09-29 |
20110236414 | Bacterial Polysaccharide-Polypeptide Conjugate Compositions - The present invention relates to improved bacterial polysaccharide-polypeptide conjugate compositions, pharmaceutical compositions comprising such bacterial polysaccharide-polypeptide conjugate compositions, and the use of such compositions. Furthermore, the invention relates to the use of a combination of a peptide of the formula R | 2011-09-29 |
20110236415 | VIRULENT ONCOLYTIC HERPES SIMPLEX VIRUS STRAINS ENGINEERED TO COUNTER THE INNATE HOST RESPONSE - The present invention relates to an avirulent, oncolytic herpes simplex virus modified from a wild-type herpes simplex virus so that both γ | 2011-09-29 |
20110236416 | FOOT AND MOUTH DISEASE VIRUS RECOMBINANT VACCINES AND USES THEREOF - The present invention encompasses FMDV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing FMDV antigens. The invention also encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or porcines, against FMDV. | 2011-09-29 |
20110236417 | VACCINES COMPRISING MUTANT ATTENUATED INFLUENZA VIRUSES - The invention provides a vaccine comprising an effective amount of an isolated recombinant influenza virus comprising a mutant M gene segment that is mutated so that upon viral replication the mutant M gene expresses a functional M1 protein and a mutant M2 protein with a deletion of the cytoplasmic tail and either lacking a transmembrane domain or having a mutated transmembrane domain. | 2011-09-29 |
20110236418 | Materials and Methods for Improved Vaccination - The invention relates to materials and methods for improved vaccination strategies and in particular to the use of lentivirus comprising nucleic acid encoding an antigen, or antigen presenting cells transduced with such lentivirus, to stimulate immune responses against the encoded antigen, in heterologous prime-boost vaccination regimes. | 2011-09-29 |
20110236419 | RECOMBINANT CDV COMPOSITIONS AND USES THEREOF - The present invention provides vectors that contain and express in vivo or in vitro CDV polypeptides or antigens that elicit an immune response in animal against CDV, compositions comprising said vectors and/or CDV polypeptides, and methods of vaccination against CDV. The invention further provides methods for inducing an immunogenic or protective response against CDV and other canine virus, as well as methods for preventing or treating CDV and other canine virus or disease state(s) caused by CDV and other canine virus. | 2011-09-29 |
20110236420 | BLUETONGUE VIRUS RECOMBINANT VACCINES AND USES THEREOF - The present invention encompasses BTV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing BTV antigens. The invention also encompasses recombinant vectors encoding and expressing BTV antigens, epitopes or immunogens which can be used to protect animals, such as ovines, bovines, or caprines, against BTV. | 2011-09-29 |
20110236421 | FLAVIVIRUS HOST RANGE MUTATIONS AND USES THEREOF - Methods and compositions concerning mutant flaviviruses with host range mutations. In some embodiments the invention concerns nucleotide sequences that encode mutant flavivirus proteins. Viruses comprising these sequences that display reduced replication in mammalian cells are provided. In further aspects of the invention, flavivirus vaccine compositions are provided. In another embodiment the invention provides methods for vaccination against flavivirus infection. | 2011-09-29 |
20110236422 | VARIANTS OF HEPATITIS B VIRUS WITH RESISTANCE TO ANTI-VIRAL NUCLEOSIDE AGENTS AND APPLICATIONS THEREOF - The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus. | 2011-09-29 |
20110236423 | IMMUNOGENIC AGENTS AGAINST BURKHOLDERIA PSEUDOMALLEI AND/OR BURKHOLDERIA MALLEI, COMPRISING LIPOPOLYSACCHARIDE, CAPSULAR POLYSACCHARIDE AND/OR PROTEINS FROM BURKHOLDERIA PSEUDOMALLEI - An immunogenic agent which comprises a killed strain of | 2011-09-29 |
20110236424 | TREATING ALLERGY WITH DETOXIFIED E. COLI HEAT-LABILE ENTEROTOXIN - A method for treating allergy with a pharmaceutical composition containing a detoxified | 2011-09-29 |
20110236425 | ANTHRAX VACCINE FORMULATION AND USES THEREOF - An anthrax vaccine with alhydrogel as the adjuvant is presented in a composition formulated by mixing rPA with colloidal alhydrogel (alum) adjuvant to produce the final product, comprising 200 μg/ml rPA bound to 0.26% alhydrogel in phosphate buffered saline (PBS), said formulation containing an optimal concentration of phosphate. Methods of using the vaccines to treat or prevent infections are also presented. | 2011-09-29 |
20110236426 | PHARMACEUTICAL PRODUCT FOR UP-DOSING OF ALLERGY VACCINE - This invention relates to the use of a pharmaceutical product comprising allergen and optionally an adjuvant for fast up-dosing in connection with allergy vaccination wherein a reduced number of injections are used. The invention also relates to the pharmaceutical product as such. | 2011-09-29 |
20110236427 | Antagonists of NR2F6 For Augmenting The Immune Response - The present invention relates to antagonists/inhibitors of NR2F6 (nuclear orphan receptor receptor Ear2) for the treatment of a disease related to an insufficient immune response. Furthermore, pharmaceutical compositions comprising said antagonists/inhibitors of NR2F6 and a pharmaceutical carrier are comprised. In a further aspect, the present invention provides for a method for identifying immunoaugmenting agents comprising contacting a cell, tissue or a non-human animal comprising a reporter construct for NR2F6-inhibition with a candidate molecule, measuring the reporter signal and selecting a candidate molecule which alters the reporter signal. Furthermore, the present invention relates to the non-human transgenic animals or cells or tissue derived therefrom useful in the provided methods for identifying immunoaugmenting agents. In yet another aspect, the present invention relates to ligand-mediated reporter gene expression constructs, ligand displacement constructs, fluorescent cellular sensor fusion mutant constructs and ligand-induced homo- and/or heterodimer constructs useful in the provided methods for identifying immunoaugmenting agents. | 2011-09-29 |
20110236428 | COMBINATION THERAPY WITH PEPTIDE EPOXYKETONES - The invention provides combination therapy, wherein one or more other therapeutic agents are administered agents are administered with peptide epoxyketones or a pharmaceutically acceptable salt thereof. Another aspect of the invention relates to treating cancer with a peptide epoxyketone administered in combination with another therapeutic agent. | 2011-09-29 |
20110236429 | Small Cationic Antimicrobial Peptides - The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides. | 2011-09-29 |
20110236430 | METHOD FOR CONTROLLING TOXICITY OF METALLIC PARTICLE AND LOW-TOXICITY COMPOSITE OF METALLIC NANOPARTICLE AND INORGANIC CLAY - The present invention provides a method for controlling toxicity of metallic particles and a low-toxicity composite of metallic nanoparticles and inorganic clay. The metallic nanoparticles are effective in preventing infection and in skinning over, and thus suitable for treating scalds/burns. In the composite, the weight ratio of metallic nanoparticles to inorganic clay preferably ranges 0.1/99.9 to 6.0/94.0 in a size of about 5 to 100 nm. Preferably, the metal is silver and the inorganic clay is nano silicate platelets. | 2011-09-29 |
20110236431 | TREATMENT OF ACUTE MYOCARDIAL INFARCTION (AMI) USING ENCAPSULATED CELLS ENCODING AND SECRETING GLP-1 PEPTIDES OR ANALOGS THEREOF - The present application refers to the use of cells, e.g. mesenchymal stem cells or mesenchymal stromal cells, or any further suitable cell, encoding and secreting GLP-1, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof, for the treatment of acute myocardial infarction (AMI or Ml), wherein the cells, encoding and secreting GLP-1, a fragment or variant thereof or a fusion peptide comprising GLP-1 or a fragment or variant thereof, are encapsulated in a (spherical) microcapsule to prevent a response of the immune system of the patient to be treated. The present application also refers to the use of these (spherical) microcapsule(s) or of a pharmaceutical composition containing these cells or (spherical) microcapsule(s) for the treatment of acute myocardial infarction (AMI or Ml). | 2011-09-29 |
20110236432 | Coated Medical Device and Method of Coating a Medical Device to Reduce Fibrosis and Capsule Formation - Coating for a medical device comprising cell-adhesive proteins having the ability to reduce fibrous reaction, said coating being in the form of separate islets having an individual area which is less than 12 μm | 2011-09-29 |
20110236433 | WOUND CARE DEVICE - An absorbent wound care device includes two or more materials which individually do not gel when exposed to a fluid but do gel when brought together and exposed to a fluid. The device is particularly intended for haemostatic use and for absorbing bodily fluids being emitted from wounds and physiological target sites. | 2011-09-29 |
20110236434 | Polymorphic Forms of ST-246 and Methods of Preparation - Polymorph forms of 4-trifluoromethyl-N-(3,3 | 2011-09-29 |
20110236435 | ENHANCED BONE CELLS GROWTH AND PROLIFERATION ON TiO2 NANOTUBULAR SUBSTRATES TREATED BY RADIO-FREQUENCY PLASMA DISCHARGE - A method for growing bone cells. In one aspect, the present invention provides a method for growing bone cells, comprising the steps of (a) anodizing a titanium substrate to form an array of titanium dioxide nanotubes on a surface of the titanium substrate, (b) subjecting the anodized titanium substrate to a radio frequency plasma discharge to chemically modify the array of titanium dioxide nanotubes formed on the surface of the titanium substrate, (c) seeding bone cells onto the surface of the titanium substrate that has an array of titanium dioxide nanotubes thereon after the subjecting step, and (d) incubating the seeded bone cells for a period of time effective for the cells to grow and proliferate. | 2011-09-29 |
20110236436 | PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE - A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a dissolution rate of the drug from the composition is less than 85% after 30 minutes from the beginning of a dissolution test, is disclosed. | 2011-09-29 |
20110236437 | NANOPARTICLES AND METHODS OF USE - Provided herein are nanoparticles and methods for using nanoparticles. The nanoparticles include at least three antiretroviral agents. When introduced to cells the nanoparticles cause an increase in the intracellular concentration of the antiretroviral agents to a level that is at least the IC50 against HIV-I or HIV-2. This concentration may be maintained for at least 21 days after the cells are contacted with the nanoparticle. When administered to a subject the nanoparticles cause the concentration of the antiretroviral agents to increase to at least 100 ng/ml in the serum of the subject, at least 0.5 μg/gram tissue in an organ of the subject, or a combination thereof. Such a concentration may be maintained for at least 21 days after the administration. | 2011-09-29 |
20110236438 | METHOD OF TREATMENT OF DISEASES USING HOODIA EXTRACTS - A method for treating a disease comprising administering to a mammal in need thereof an effective dosage of an extract of a plant of the genus | 2011-09-29 |
20110236439 | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane - The present invention relates to an immediate release solid oral dosage form containing 1-aminocyclohexanes, preferably memantine or neramexane, and optionally a pharmaceutically acceptable coating, wherein the active ingredient exhibits dose proportionality and is released at a dissolution rate of more than about 80% within about the first 60 minutes following entry of said form into a use environment. The dosage form is direct compressed and has a hardness within the range of between about 3 and about 40 Kp, exhibits an average T | 2011-09-29 |
20110236440 | MEDICAL TAPE PREPARATION - A medical tape preparation which comprises a support and, superposed on one side thereof in the following order, a pressure-sensitive adhesive layer and a release liner. The pressure-sensitive adhesive layer can contain a large amount of an oleophilic oily matter. The tape preparation is excellent in adhesion, cohesiveness, and stability even when no crosslinking agent is used. The pressure-sensitive adhesive layer in the medical tape preparation comprises a blend of two tacky polymers, which are a tacky polymer (A) comprising a copolymer obtained from 2-acetoacetoxyethyl methacrylate and other vinyl monomer(s) as constituent ingredients and a tacky polymer (B) comprising a copolymer which is obtained from a C | 2011-09-29 |
20110236441 | ANTIMICROBIAL SUBSTRATES AND USES THEREOF - A new substrate makes it possible to modify surface properties relating to antimicrobial properties. Said substrate has an electron donating surface, characterized in having metal particles on said surface, said metal particles comprising palladium and at least one metal chosen from gold, ruthenium, rhodium, osmium, iridium, and platinum, wherein the amount of said metal particles is from about 0.001 to about 8 μg/cm | 2011-09-29 |
20110236442 | SOLID ORAL SENSORIAL PRODUCTS INCLUDING STAIN INHIBITOR - A solid oral sensorial product includes at least one botanical material and at least one phosphate containing stain inhibitor. The botanical material is selected from the group consisting of tobacco, tea, coffee, cocoa, and combinations thereof. | 2011-09-29 |
20110236443 | MULTILAYER MELT-EXTRUDED FILM - High amounts of active ingredients, such as drugs, can be incorporated into a multilayer melt-extruded film which comprises i) one or more active ingredient layers produced from a melt-extruded polymer composition comprising a) a water-soluble polymer and b) an active ingredient; and ii) one or more removable protective layers which leave the active ingredient layer(s) substantially intact upon removal of the protective layer(s). | 2011-09-29 |
20110236444 | Antimicrobial Silica Composites - The composites disclosed herein comprise silica and an antimicrobial metal oxide. The composites are useful in inhibiting microbial growth and are therefore useful in a variety of applications, including, for example, as components in dentifrice compositions. | 2011-09-29 |
20110236445 | MOUTHWASH IN THE FORM OF A STABLE SUSPENSION COMPRISING MICROSPHERES THAT INCORPORATE AN ACTIVE INGREDIENT - The present invention relates to a mouthwash including microspheres that incorporate an active ingredient, wherein the microspheres are obtained directly in situ in the aqueous phase of the mouthwash by cross-linking. These microspheres do not tend to aggregate and the mouthwash appears in the form of a homogenous and stable suspension even after prolonged storage. | 2011-09-29 |
20110236446 | HYDROGEL PARTICLES - Hydrogel particles include a continuous phase portion of non-crosslinked hydrogel and disperse phase portions dispersed in the continuous phase portion. Each of the disperse phase portions contains a solid oil and a liquid oil as an oil component, and titanium oxide particles dispersed therein. The solid oil of the oil component contains a higher alcohol and a solid paraffin, and the content of the solid oil in the disperse phase portion is 1 to 12 mass %. The hydrogel particles have a volume-average particle diameter of 10 to 300 μm. | 2011-09-29 |
20110236447 | Oil-In-Water Cosmetics - The present invention provides an oil-in-water cosmetic excellent in emulsion stability. The oil-in-water cosmetic includes (a) oil-droplet particles consisting of an oil component to be emulsified; (b) vesicle particles for stabilizing the oil-droplet particles; and (c) an aqueous phase containing water and a monohydric aliphatic alcohol having 1 to 4 carbon atoms. It is preferred that the vesicle particles are formed with an amphiphilic substance which spontaneously forms vesicle particles, and that they are localized on surfaces of the oil-droplet particles. It is preferred that the amphiphilic substance be a polyoxyethylene hydrogenated castor oil derivative represented by the following formula (1), wherein E=L+M+N+X+Y+Z, and that said E which represents the average addition mole number of ethylene oxide is 10 to 20. | 2011-09-29 |
20110236448 | Methods and Apparatus for Passive Reduction of Nosocomial Infections in Clinical Settings, and Fabrics, Yarns, and Filaments for Use in Connection Therewith - A method for passively reducing nosocomial infections by providing fabrics for patient contact only as media for air filtration in areas with patient populations, which fabrics have been treated with a solution of eugenol of sufficient strength and for sufficient time to reduce the percentage of viable microbes in the fabrics by at least 2 log units. | 2011-09-29 |
20110236449 | Caramel-coated insecticide - An insect bait comprising particles of an insect-killing compound onto which a coating of insect attracting material has been applied, and the method by which this bait is prepared. | 2011-09-29 |
20110236450 | POLYELECTROLYTE COMPLEXES - The present invention relates to aqueous compositions of associative polyelectrolyte complexes (PECs), optionally containing surfactants, biocidal agents and/or oxidants, which can provide a cleaning benefit and surface protection to treated articles including reduced soiling tendency, reduced cleaning effort and improved soil repellancy, as well as providing bacteriostatic properties to treated surfaces that thereby gain resistance to water, environmental exposure and microbial challenge. Treatment means and compositions are provided that employ associative polyelectrolyte complexes formed by combining a water soluble cationic first polyelectrolyte with a water soluble second polyelectrolyte bearing groups of opposite charge to the first polyelectrolyte under suitable mixing conditions and at least one oxidant selected from the group: alkaline metal salts and/or alkaline earth metal salts of hypochlorous acid, hypochlorous acid, solubilized chlorine, any source of free chlorine, acidic sodium chlorite, active chlorine generating,compound and any combinations or mixtures thereof. Also provided are means to form stable associative polyelectrolyte complexes with at least one oxidant in aqueous solutions having R values from about 0.10 to 20. | 2011-09-29 |
20110236451 | Multipurpose Ant Bait - Subject of the present invention is a solid ant bait comprising an insecticide and a bait composition. Another subject is a process for the preparation of said ant bait, comprising extruding a mixture, which contains the insecticide and the bait composition. Yet another subject is a method for controlling ants, comprising offering to said ants the ant bait according to the invention. Finally, a subject is a use of the ant bait according to the invention for controlling ants. | 2011-09-29 |
20110236452 | METHOD FOR PRODUCING AGRICHEMICAL-CONTAINING RESIN COMPOSITION - Disclosed is a method which can readily design an agricultural chemical-containing resin composition having a desired release rate history and can produce the agricultural chemical-containing resin composition. Specifically disclosed is a method for producing an agricultural chemical-containing resin composition, including: respectively selecting an acetamiprid content Ac | 2011-09-29 |
20110236453 | TREATMENT OF BIOFILMS - The present invention relates to a peptide or peptidomimetic for use in the treatment of a biofilm-associated infection in a subject, wherein said peptide or peptidomimetic a) carries a net positive charge, b) is 1 to 6 amino acids in length or is an equivalently sized peptidomimetic; and c) is amphipathic in nature, having one or more lipophilic groups, one of said lipophilic groups comprising at least 7 non-hydrogen atoms. | 2011-09-29 |
20110236454 | INJECTABLE DRUG DELIVERY FORMULATION - The invention provides an injectable formulation that includes an active agent; a biocompatible solvent system, crosslinkable polymers such as polysaccharides; and crosslinking agents; wherein the formulation is substantially free of water. The invention also provides a drug delivery depot formed from the injectable formulation wherein the polymers crosslink in the presence of water in the body of a patient, or in the air, prior to implantation in the patient. Also provided are methods of treatment using such formulations and drug delivery systems. | 2011-09-29 |
20110236455 | Novel Regulators of the Innate Immune System - The present invention relates to the identification of novel regulators of the innate immune system, in particular the complement system. More particularly, the present invention relates to specific C5 convertase inhibitors. These novel inhibitors are particularly useful for treating inflammatory diseases involving the complement system. In a first aspect, the present invention focuses on the use of CFHR proteins and functional fragments or functional derivatives thereof for preventing inflammatory reactions. In a further aspect, the present invention focuses on the use of said CFHR proteins for inactivating complement activation during transplantation and dialysis and for coating devices which come into contact with blood or body fluids, in particular implants. The invention furthermore provides a pharmaceutical composition comprising functional CFHR protein in combination with functional factor H. In a further aspect, the present invention focuses on providing monoclonal antibodies which specifically detect CFHR proteins, and on the use thereof in methods of determining CFHR in body fluids. These methods are particularly suitable for diagnosing inflammatory diseases. | 2011-09-29 |
20110236456 | IMPLANTABLE DEVICE FOR THE DELIVERY OF HISTRELIN AND METHODS OF USE THEREOF - This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active histrelin at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of histrelin to tissues or organs. | 2011-09-29 |
20110236457 | Micronized Device for the Delivery of Biologically Active Molecules and Methods of Use Thereof - The invention provides micronized encapsulated cell therapy devices that are capable of delivering a biologically active molecule to the eye. Also provided are methods of using the same to deliver biologically active molecules to the eye and to treat ophthalmic disorders in patients suffering there from. | 2011-09-29 |
20110236458 | COATING - The invention relates to a coating composition for an implantable medical device, a method of coating a medical device and a device coated with the composition. | 2011-09-29 |
20110236459 | Therapeutic Implant - Surgical implants of the present disclosed include a film comprising a first therapeutic agent and a mesh comprising a second therapeutic agent. The surgical implant includes a film in direct contact with a mesh. The first therapeutic agent may be released at a first rate and the second therapeutic agent may be released at a second rate. | 2011-09-29 |
20110236460 | Therapeutic Implant - Surgical implants of the present disclosed include a film comprising a first therapeutic agent and a mesh comprising a second therapeutic agent. The surgical implant includes a film in direct contact with a mesh. The first therapeutic agent may be released at a first rate and the second therapeutic agent may be released at a second rate. | 2011-09-29 |
20110236461 | METHODS FOR STIMULATING CHONDROGENESIS UTILIZING A POTASSIUM CHANNEL INHIBITOR - The invention is directed to a method for stimulating chondrogenesis comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of a potassium channel inhibitor. | 2011-09-29 |
20110236462 | INTRAVAGINAL DRUG DELIVERY DEVICE - Described herein is an intravaginal drug delivery system. In an embodiment the intravaginal drug delivery system includes a progestin and estrogen compound, and releases the active ingredients in a fixed physiological ratio over a prolonged period of time to produce a contraceptive state in a female. | 2011-09-29 |
20110236463 | FORMULATIONS FOR SYSTEMIC BUCCAL DELIVERY COMPRISING S-ADENOSYLMETHIONINE, THEIR PREPARATION AND USE - Formulations for systemic buccal delivery, in particular chewing gums, chewable tablets, orodispersible tablets, oromucosal preparations comprising sulpho-adenosyl-L-methionine (SAMe) which allows the absorption of the active principle through the oral mucosa are described. | 2011-09-29 |
20110236464 | MEMBRANE - The invention relates to a membrane for supporting cells, especially RPE cells. The membrane is useful in the treatment of conditions such as age related macular degeneration. | 2011-09-29 |
20110236465 | MELT-EXTRUDED FILM - A mono-layer or multi-layer film wherein at least one of the layers has a thickness of at least 0.125 mm is produced from a melt-extruded polymer composition comprising a) a water-soluble polymer, b) an active ingredient and c) an adjuvant selected from the group consisting of mono- and disaccharides, sugar alcohols, low molecular weight water soluble polymers, and salts of cross-linked carboxymethylcellulose, with the proviso that the adjuvant c) is different from the water-soluble polymer a). | 2011-09-29 |
20110236466 | CHEMO VECTOR THERAPY TO DELIVER CHEMOTHERAPY MOLECULES TO SPECIFIC CELLS TO MANAGE BREAST CANCER, OTHER CANCERS AND INFLAMMATORY DISORDERS - The innovative treatment strategy described here utilizes configurable microscopic medical payload delivery devices to act as a transport means to deliver chemotherapy molecules to specific cell types in the body. Utilizing probes present on the exterior of the transport device, transport device locates specific target cell types in the body. Once a specific target cell type has been encountered, the configurable microscopic medical payload delivery device inserts its payload of chemotherapy molecules into the target cell type. By delivering chemotherapy molecules into specific cells, the growth of the specific cells can be stifled. Delivering chemotherapy molecules into specific cancer cells inhibits the rate of growth and rate of cell reproduction of the cancer cells. Utilizing configurable microscopic medical payload delivery devices to insert chemotherapy into targeted cancer cells or inflammatory cells effectively manages cancer, inflammatory arthritis and other inflammatory conditions, while preventing unwanted side effects. | 2011-09-29 |
20110236468 | VACCINE COMPOSITIONS - The present invention relates, inter alia, to a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more viral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the one or more first immunogenic polypeptides, the one or more viral vectors and the adjuvant are administered concomitantly. The invention also relates to vaccines, pharmaceutical compositions, kits and uses employing said polypeptides, viral vectors and adjuvants. | 2011-09-29 |
20110236469 | POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF - The present invention relates to polynucleotides encoding immunogenic HIV type C Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of Gag- and/or Env-containing proteins are also described. | 2011-09-29 |
20110236470 | GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS - The present invention relates to polypeptide fragments, including variants and analogs, of | 2011-09-29 |
20110236471 | PLATINUM COMPLEXES AND METHODS FOR INHIBITING TUMOR CELL PROLIFERATION - The subject invention concerns platinum complexes that exhibit antitumor cell and/or antiparasitic activity. The subject invention also concerns the use of platinum complexes of the invention to treat oncological and inflammatory disorders. The platinum complexes of the invention can also be used to treat or prevent infection by a virus or a bacterial or parasitic organism in vivo or in vitro. | 2011-09-29 |
20110236472 | DRUG DELIVERY SYSTEM FOR ADMINISTRATION OF A WATER SOLUBLE, CATIONIC AND AMPHIPHILIC PHARMACEUTICALLY ACTIVE SUBSTANCE - A drug delivery system (DDS) for administration of a water soluble, cationic, and amphiphilic pharmaceutically active substance (API) which DDS comprises amorphous particles of <100 nm of a poorly water soluble complex of the API with a Na-salt of N-all-trans-retinoyl cysteic acid methyl ester and/or a Na-salt of N-13-cis-retinoyl cysteic acid methyl ester, which particles are entrapped in nanoparticles formed a Na-salt of N-all-trans-retinoyl cysteic acid methyl ester and/or a Na-salt of N-13-cis-retinoyl cysteic acid methyl ester, the w/w-ratio of Na-salt of N-alltrans-retinoyl cysteic acid methyl ester and/or a Na-salt of N-13-cis-retinoyl cysteic acid methyl ester to the complex is about 0.5:1 to about 20:1. A pharmaceutical composition comprising such a DDS. Methods for preparation of such a DDS and such a pharmaceutical composition. Use of such a DDS and pharmaceutical composition for treatment of cancer. | 2011-09-29 |
20110236473 | STABLE ALISKIREN FORMULATIONS - An oral pharmaceutical formulation, made up of croscarmellose sodium and internal granules including a pharmaceutically acceptable salt or polymorph of aliskiren and stearic acid. | 2011-09-29 |
20110236474 | Pharmaceutical Compositions of Selective Factor Xa Inhibitors for Oral Administration - The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in an object after oral administration comprising orally administering a pharmaceutical composition as described above. | 2011-09-29 |
20110236475 | GRANULAR PHARMACEUTICAL COMPOSITIONS - Pharmaceutical compositions comprising a plurality of formulated particles containing at least one active ingredient and at least one pharmaceutically acceptable excipient, granulated with a granulating composition containing at least one pharmaceutical excipient. | 2011-09-29 |
20110236476 | PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND NICOTINIC ACID AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising eicosapentaenoic acid and/or derivatives thereof and nicotinic acid, to methods of manufacturing such compositions, and to therapeutic methods for treating carious diseases and disorders. | 2011-09-29 |
20110236477 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF - The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a SGLT-2 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases. | 2011-09-29 |